The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR
Authors
Keywords
Cancer, PI3K, EGFR, Gallbladder carcinoma
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 35, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-06-18
DOI
10.1186/s13046-016-0370-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Zinc finger X-chromosomal protein (ZFX) is a significant prognostic indicator and promotes cellular malignant potential in gallbladder cancer
- (2015) Hao Weng et al. CANCER BIOLOGY & THERAPY
- AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
- (2015) Moshe Elkabets et al. CANCER CELL
- Fibronectin promotes cell proliferation and invasion through mTOR signaling pathway activation in gallbladder cancer
- (2015) Yang Cao et al. CANCER LETTERS
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- Public Health in the Precision-Medicine Era
- (2015) Ronald Bayer et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer
- (2015) Ana Bosch et al. Science Translational Medicine
- Baicalein Inhibits Progression of Gallbladder Cancer Cells by Downregulating ZFX
- (2015) Tian-Yu Liu et al. PLoS One
- Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition
- (2014) Gaofeng Xiong et al. BMC CANCER
- Ursolic acid induces cell cycle arrest and apoptosis of gallbladder carcinoma cells
- (2014) Hao Weng et al. Cancer Cell International
- Yes-associated protein 1 (YAP1) promotes human gallbladder tumor growth via activation of the AXL/MAPK pathway
- (2014) Maolan Li et al. CANCER LETTERS
- Triptolide Induces S Phase Arrest and Apoptosis in Gallbladder Cancer Cells
- (2014) Yun-Ping Hu et al. MOLECULES
- Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia
- (2014) Monique Dail et al. NATURE
- Identification of genomic alterations in oesophageal squamous cell cancer
- (2014) Yongmei Song et al. NATURE
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- (2014) Dejan Juric et al. NATURE
- Endophilin marks and controls a clathrin-independent endocytic pathway
- (2014) Emmanuel Boucrot et al. NATURE
- Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway
- (2014) Maolan Li et al. NATURE GENETICS
- Gain of Interaction with IRS1 by p110α-Helical Domain Mutants Is Crucial for Their Oncogenic Functions
- (2013) Yujun Hao et al. CANCER CELL
- Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
- (2013) J Lemke et al. CELL DEATH AND DIFFERENTIATION
- Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
- (2013) Yuchen Jiao et al. NATURE GENETICS
- The p110 and p110 isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis
- (2012) T. Utermark et al. GENES & DEVELOPMENT
- Structural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases
- (2011) Oscar Vadas et al. Science Signaling
- The emerging mechanisms of isoform-specific PI3K signalling
- (2010) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now